Filing Details

Accession Number:
0001415889-23-006738
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2023-04-19 18:01:51
Reporting Period:
2023-02-27
Accepted Time:
2023-04-19 18:01:51
Original Submission Date:
2023-02-28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1159036 Halozyme Therapeutics Inc. HALO Biological Products, (No Disgnostic Substances) (2836) 880488686
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1507174 J. Michael Labarre C/O Halozyme Therapeutics, Inc.
12390 El Camino Real
San Diego CA 92130
Svp, Chief Technical Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-02-27 2,984 $18.41 144,895 No 4 M Direct
Common Stock Disposition 2023-02-27 2,984 $49.55 141,911 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Option to Purchase Common Stock Disposition 2023-02-27 2,984 $0.00 2,984 $18.41
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
37,505 2028-02-14 No 4 M Direct
Footnotes
  1. The option exercise and sale reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person.
  2. This amendment is being filed to include the option exercise information in Tables I and II and to update the information in Table I, Column 5.
  3. Represents a weighted average sales price per share. These shares were sold at prices ranging from $49.36 to $49.80. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  4. This option was granted on February 14, 2018 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.